Designer Synthetic Opioids Beyond Fentanyl & Nitazenes: Master Harm-Reduction Monograph

Designer Synthetic Opioids Beyond Fentanyl & Nitazenes: Master Harm-Reduction Monograph

Emergency safety: Unknown synthetic opioids can cause rapid respiratory depression. If someone is unresponsive, difficult to wake, breathing slowly or irregularly, blue/gray around the lips, choking/gurgling while unconscious, or has collapsed after an unknown pill, powder, vape, or “research chemical,” call emergency services and give naloxone if available.

Quick answer

The modern synthetic-opioid market is much broader than fentanyl.

It is also broader than the nitazenes.

Over the last decade, illicit and gray markets have cycled through multiple chemically unrelated opioid families, including:

• U-series / benzamide opioids such as U-47700;
• benzimidazolone/orphine opioids such as brorphine, chlorphine and cychlorphine;
• cinnamylpiperazine opioids such as 2-methyl-AP-237 and AP-238;
• other short-lived synthetic-opioid scaffolds.

These families look different chemically.

Clinically, the main threat converges on the same mechanism:

mu-opioid receptor activation → sedation → respiratory depression → hypoxia → death.

That shared mechanism also creates:

• tolerance;
• physical dependence;
• opioid withdrawal;
• opioid use disorder;
• loss-of-tolerance overdose risk.

The key harm-reduction skill is therefore not memorizing every chemical name.

It is recognizing opioid pharmacology under conditions of uncertain identity.

---

Why this category exists

A common misconception is:

“If it is not fentanyl, it is not part of the synthetic-opioid problem.”

That is false.

Forensic literature repeatedly shows new opioid scaffolds appearing when earlier compounds become controlled, less available, or easier for laboratories to detect. PMID 36103391

This is often called market substitution or chemical replacement.

The result is a moving target:

These waves can overlap.

---

The recurring origin story: old chemistry becomes a new street drug

Many designer opioids were not invented by recreational-drug sellers.

They were rediscovered from:

• pharmaceutical research;
• medicinal-chemistry papers;
• patents;
• abandoned analgesic programs.

U-47700

Developed by Upjohn in the 1970s as part of opioid analgesic research.

2-Methyl-AP-237

Descended from the bucinnazine/AP-237 piperazine-opioid lineage.

Brorphine

A later benzimidazolone opioid that entered markets around 2019.

The danger appears when a molecule with potent opioid biology enters an environment with:

• no pharmaceutical manufacturing controls;
• no labeled therapeutic dose;
• no reliable identity;
• little clinical familiarity.

---

Different chemistry, same dangerous endpoint

Most of the compounds covered here activate the mu-opioid receptor (MOR).

MOR activation can produce:

• analgesia;
• euphoria;
• sedation;
• miosis;
• respiratory depression;
• constipation;
• tolerance;
• physical dependence.

Why structural family still matters

Although MOR is shared, different scaffolds can have different:

• potency;
• receptor efficacy;
• metabolism;
• active metabolites;
• duration;
• tissue distribution;
• detectability.

That means fentanyl experience cannot be used to precisely predict U-47700, brorphine or 2-methyl-AP-237.

---

U-series / benzamide opioids

U-47700

U-47700 is the best-known non-fentanyl U-series opioid.

It became a major recreational NPS and appeared in:

• powder;
• counterfeit oxycodone;
• counterfeit alprazolam;
• “gray death” opioid mixtures.

Human clinical literature documents:

• depressed consciousness;
• reduced respiratory rate;
• pulmonary edema;
• fatal intoxication.

See the U-47700 masterclass monograph.

Why U-47700 remains educationally important

It demonstrates that an opioid can be:

• structurally unrelated to fentanyl;
• missed by routine testing;
• resurrected from old medicinal chemistry;
• sold as a familiar prescription pill.

That pattern repeats with later NPS opioids.

---

Brorphine and the orphines

Brorphine is a benzimidazolone opioid.

It emerged in 2019–2020 as isotonitazene detections declined.

In an early U.S. 20-case series:

• fentanyl was present in every case;
• flualprazolam was present in 80%.

Brorphine later turned out to be a preview of a broader orphine family.

By 2026, forensic surveillance was tracking compounds including:

• chlorphine;
• cychlorphine;
• spirochlorphine;
• spirobrorphine;
• dichloro-brorphine analogues.

See:

• Brorphine masterclass monograph
• Orphine opioids
• Cychlorphine

---

Cinnamylpiperazine opioids

This family includes:

• AP-237 / bucinnazine;
• 2-methyl-AP-237;
• AP-238;
• related analogues.

Unlike many RC opioids, the parent bucinnazine has a history of medical use in China.

That should not be mistaken for evidence that unregulated derivatives are pharmaceutical products.

A 2022 study directly confirmed MOR activity and postmortem cases involving both 2-methyl-AP-237 and AP-238. PMID 35275255

See the 2-Methyl-AP-237 & AP-238 masterclass monograph.

---

The overdose syndrome: focus on physiology, not the seller's name

If the chemical is unknown, the clinical signs matter more than the package.

Possible opioid overdose signs include:

• extreme sleepiness;
• inability to wake;
• slow or shallow breathing;
• stopped breathing;
• blue/gray lips;
• pinpoint pupils;
• collapse;
• choking/gurgling while unresponsive.

Do not wait for a laboratory result before treating a likely opioid emergency.

---

Naloxone

Naloxone remains the key opioid-overdose reversal medication.

It is appropriate when opioid toxicity is suspected even if:

• the exact analogue is unknown;
• a routine drug screen is negative;
• the product was sold as something else;
• multiple drugs may be present.

What naloxone cannot do

Naloxone does not reverse:

• benzodiazepines;
• alcohol;
• xylazine;
• synthetic cannabinoids;
• stimulant toxicity.

A person can therefore remain dangerously sedated or medically unstable after the opioid component improves.

Emergency care remains important.

---

Recurrent toxicity

Some opioid effects can outlast naloxone.

A person may:

1. improve;
2. appear awake;
3. become sedated again.

This is especially concerning when:

• duration is unknown;
• multiple opioids are present;
• long-acting sedatives are co-used;
• the product contains an unfamiliar NPS.

---

Counterfeit pills: one of the biggest exposure routes

Novel synthetic opioids have repeatedly appeared in tablets made to resemble familiar prescriptions.

Historically, counterfeit pills have contained:

• fentanyl analogues;
• U-47700;
• other NSOs.

The larger lesson is not tied to one drug:

A pharmaceutical-looking tablet from an unregulated supply is not a pharmaceutical product.

Shape, imprint and color cannot establish chemical identity.

---

Substitution and hidden exposure

Modern surveillance has found novel opioids in products represented as:

• heroin;
• fentanyl;
• oxycodone;
• alprazolam;
• ketamine;
• THC/cannabinoid vapes;
• other NPS.

This means someone can have an opioid overdose without knowingly choosing an opioid.

That is why naloxone access matters beyond people who self-identify as opioid users.

---

Polysubstance overdose

Novel opioid cases frequently involve:

• fentanyl;
• benzodiazepines;
• stimulants;
• alcohol;
• xylazine;
• multiple novel opioids.

Opioids + benzodiazepines

This combination is especially dangerous because:

• opioids suppress respiratory drive;
• benzodiazepines deepen sedation and impair arousal.

Multiple opioids

Two MOR agonists can produce greater respiratory depression than the user expects from either product label.

---

Tolerance

Tolerance means repeated opioid exposure reduces some effects.

It can lead to:

• escalating use;
• more frequent use;
• stronger physical dependence.

Tolerance is not complete protection from respiratory depression.

Loss of tolerance

Tolerance can fall after:

• abstinence;
• hospitalization;
• detoxification;
• incarceration;
• substantial reduction.

Returning to prior exposure patterns can then create extreme overdose risk.

---

Physical dependence

Any repeatedly used potent MOR agonist can plausibly produce physical dependence.

Dependence means:

stopping or substantially reducing the drug causes withdrawal.

This is not identical to addiction.

For novel opioids, the evidence may fall into three tiers:

1. direct compound-specific human withdrawal evidence;
2. nitazene/related-class human evidence;
3. MOR pharmacology + opioid-class inference only.

A high-quality monograph should always tell readers which tier applies.

---

Withdrawal

Opioid withdrawal can include:

• restlessness;
• anxiety;
• insomnia;
• sweating/chills;
• yawning;
• runny nose/tearing;
• gooseflesh;
• abdominal cramps;
• vomiting/diarrhea;
• muscle aches;
• rapid pulse;
• craving.

Why NPS withdrawal is hard to predict

The person may not know:

• which opioid they used;
• the concentration;
• whether the product changed;
• whether more than one opioid was present;
• whether a benzodiazepine is also causing dependence.

There is no universal “RC opioid taper.”

---

Dependence vs opioid use disorder

Physical dependence is a physiologic adaptation.

OUD involves a broader pattern such as:

• inability to cut down;
• craving;
• escalating use;
• continued use despite harm;
• hazardous use;
• work/family consequences;
• tolerance;
• withdrawal.

Someone can be dependent without meeting all OUD criteria.

Someone can also develop OUD through a mislabeled product they did not initially recognize as an opioid.

---

Treatment and support

The exact designer-opioid name does not need to be known before a person can receive evidence-based opioid treatment.

Established OUD medications include:

• buprenorphine;
• methadone;
• extended-release naltrexone in appropriately selected patients.

Clinical care can also address:

• withdrawal;
• co-occurring benzodiazepine/alcohol use;
• overdose prevention;
• mental health;
• chronic pain;
• relapse risk.

This site does not provide DIY medication induction or taper dosing.

For U.S. treatment resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

---

Why ordinary toxicology screens fail

Routine opioid immunoassays are structure-dependent.

A new opioid can activate MOR while being chemically too different from:

• morphine;
• oxycodone;
• fentanyl

to trigger the expected screening assay.

A 2025 laboratory study tested 216 fentanyl analogues and synthetic opioids across four commercial fentanyl immunoassays and found substantial variation; 28 compounds were missed by all four assays at the tested concentrations, including many emerging synthetic opioids. PMID 42441761

---

Modern analytical detection

The modern forensic standard increasingly uses:

• LC-MS/MS;
• LC-QTOF-MS;
• high-resolution mass spectrometry;
• targeted metabolite panels;
• non-targeted HRMS libraries.

A 2023 analytical review concluded that older immunoassay and GC-MS workflows are often insufficiently sensitive for increasingly potent NSOs and that LC-MS methods have become central. PMID 37221651

---

Negative screen ≠ no opioid

This deserves its own rule:

If the clinical picture strongly suggests opioid poisoning, a negative routine test does not reliably exclude a novel synthetic opioid.

Treatment should follow the clinical emergency while definitive testing catches up.

---

Forensic concentration ≠ dose

Postmortem papers often report ng/mL blood concentrations.

Those values are useful for toxicologists.

They do not tell a consumer:

• how much was ingested;
• what route was used;
• how tolerant the person was;
• whether the sample redistributed after death;
• what co-drugs were present.

A fatal concentration should never be converted into a dose recommendation or “safety margin.”

---

Why the market keeps changing

Structural bans and scheduling can reduce one drug while incentivizing another.

After broad fentanyl controls, forensic investigators saw:

• nitazenes;
• U-series derivatives;
• brorphine/orphines;
• cinnamylpiperazines.

This does not mean regulation causes every new drug.

It means illicit producers can adapt chemically when demand remains.

---

Legal status: family names are not legal categories

The phrase “designer opioid” has no single legal status.

Examples:

• U-47700: U.S. Schedule I, internationally controlled.
• Brorphine: U.S. Schedule I, internationally controlled.
• 2-Methyl-AP-237: U.S. Schedule I effective April 15, 2024; internationally Schedule I since 2023.
• AP-238: distinct molecule; do not infer status solely from 2-methyl-AP-237.
• New orphines: status varies by exact analogue and date.

Always verify:

exact compound + jurisdiction + date.

---

Special populations

Direct data for most NSO in these groups are minimal:

• pregnancy;
• breastfeeding;
• adolescents;
• older adults;
• respiratory disease;
• liver/kidney disease.

Risk is particularly high with:

• opioid-naive users;
• recent abstinence;
• benzodiazepine/alcohol co-use;
• using alone;
• counterfeit pharmaceuticals.

An absence of study data should not be mistaken for evidence of safety.

---

Myths and misconceptions

“Synthetic opioid means fentanyl.”

False.

“If fentanyl strips are negative, there is no opioid.”

False. Non-fentanyl opioids can be present.

“A novel opioid that is weaker than fentanyl is safe.”

False. U-47700 and 2-methyl-AP-237 fatalities prove otherwise.

“An old pharmaceutical patent means the drug has human safety data.”

False.

“A normal hospital opioid screen rules out overdose.”

False.

“The exact chemical must be known before naloxone can be given.”

False.

“Physical dependence means addiction.”

Not necessarily.

“All related analogues share the same legal status.”

False.

---

What we know vs what remains unknown

Established

• multiple non-fentanyl NSO families activate MOR;
• fatal respiratory depression occurs;
• counterfeit/substituted exposure occurs;
• naloxone is appropriate for opioid poisoning;
• routine screens can miss newer structures;
• polysubstance exposure is common.

Strongly class-supported

• tolerance;
• physical dependence;
• opioid withdrawal;
• loss-of-tolerance overdose risk.

Frequently unknown for an individual RC

• safe dose;
• precise half-life;
• active-metabolite contribution;
• human potency ratio;
• withdrawal timeline;
• long-term toxicity;
• pregnancy safety;
• exact legal status of newly emerging analogues.

---

Master monographs

U-series / benzamides

• U-47700

Orphines

• Brorphine
• Orphine opioids
• Cychlorphine

Cinnamylpiperazines

• 2-Methyl-AP-237 & AP-238

Adjacent family

• Nitazene opioids

---

Bottom line

The synthetic-opioid market does not move in a straight line from heroin to fentanyl.

It branches.

U-47700, brorphine, orphines, 2-methyl-AP-237 and AP-238 show that completely different chemical scaffolds can all recreate the same dangerous endpoint:

potent MOR agonism in an unregulated, rapidly changing, poorly tested supply.

The best harm-reduction strategy is therefore built around physiology and uncertainty, not brand recognition:

• recognize opioid overdose;
• carry/use naloxone;
• call emergency services;
• do not trust a pill or product label as chemistry;
• do not let a negative routine screen overrule the clinical picture;
• take dependence and withdrawal seriously;
• use established OUD treatment instead of reverse-engineering an RC dose.

Related evidence

• Nitazene opioids masterclass monograph
• Research Chemicals & NPS evidence map
• Substance Use, Dependence & Harm Reduction hub